To determine whether fecal bacteriotherapy results in a durable beneficial change in the colonic microbiota of patients with flora-related disorders.
Earlier studies have implicated the colonic microbiota in a number of conditions. Administration of a fecal suspension from a healthy individual to an ill individual (fecal bacteriotherapy) can cure Clostridium difficile infection and potentially other diseases. Oral probiotics do not work in this condition, yet there has been no study to determine whether fecal bacteriotherapy results in prolonged implantation.
Fecal samples were collected from 10 patients undergoing fecal bacteriotherapy. Patients completed an antibiotic schedule and bowel lavage before the infusion of healthy donor feces. Using a molecular approach, the bacterial populations in patient fecal samples were followed from pretreatment to 24 weeks post-initial infusion and compared with the initial infused donor fecal suspension.
At intervals of 4, 8, and 24 weeks after the procedure, the bacterial populations in the patients' fecal samples consisted predominantly of bacteria derived from the healthy donor samples. Comparisons of similarity at 4, 8, and 24 week samples to the donor-infused sample were made and each recipient's baseline sample was statistically significant with Friedman test.
This study demonstrates a durable beneficial change in the patients' bacterial populations of the colon to represent those of the healthy donor's microbiota. Manipulation of the colonic microbiota to improve its protective and beneficial role represents a promising field of new therapeutic strategies for the treatment of gastrointestinal conditions.
*Department of Gastroenterology, Nepean Hospital, Penrith
†Centre for Digestive Diseases
‡Probiotic Therapy Research Centre, Five Dock
§School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, New South Wales, Australia
The work of Dr Grehan was funded by NHMRC Medical Postgraduate Scholarship No #8136 as part of PhD studies undertaken at the University of NSW School of Microbiology and Immunology.
Reprints: Martin J. Grehan, MBBS, PhD, Department of Gastroenterology, Nepean Hospital, PO Box 63, Penrith, New South Wales 2751, Australia (e-mail: email@example.com).
Received for publication August 17, 2009; accepted April 23, 2010
Martin J. Grehan, Sharyn M. Leis, Jordana Campbell, and Hazel Mitchell has no financial interest or affiliation with any institution, organization, or company relating to the manuscript.
Thomas J. Borody has a pecuniary interest in the Centre for Digestive Diseases, where fecal bacteriotherapy is a treatment option for patients.